Clinical neuropharmacology
-
Clin Neuropharmacol · Apr 1988
Comparative Study Clinical Trial Controlled Clinical TrialComparison of controlled-release Sinemet (CR4) and standard Sinemet (25 mg/100 mg) in advanced Parkinson's disease: a double-blind, crossover study.
-
Clin Neuropharmacol · Jun 1987
Review Clinical TrialClinical presentation and neuropharmacology of restless legs syndrome.
-
Clin Neuropharmacol · Apr 1987
Clinical Trial Controlled Clinical TrialLow-dose bromocriptine in the early phases of Parkinson's disease.
The effect of bromocriptine at doses up to 20 mg/day was studied in a single-blind format with a placebo phase in 15 Parkinson's disease patients with mild-to-moderate disability who had not been previously treated with levodopa. For the 11 patients who completed the 9 month trial, both Northwestern University Disability Scale and Columbia University Rating Scale scores were significantly reduced during bromocriptine therapy, when compared with either baseline or placebo scores. ⋯ Transient side effects appeared in four patients. Bromocriptine at doses of 20 mg/day or below may yield effective symptomatic improvement in de novo parkinsonism and may be considered as the initial treatment in young parkinsonian patients with only mild-to-moderate disability.